AVITA Medical (NASDAQ:RCEL - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Monday, May 13th. Analysts expect AVITA Medical to post earnings of ($0.26) per share for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.
AVITA Medical (NASDAQ:RCEL - Get Free Report) last posted its earnings results on Thursday, February 22nd. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06. The business had revenue of $14.20 million for the quarter, compared to the consensus estimate of $14.10 million. AVITA Medical had a negative net margin of 70.56% and a negative return on equity of 54.80%. On average, analysts expect AVITA Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
AVITA Medical Stock Up 1.7 %
RCEL stock traded up $0.15 during trading on Monday, hitting $8.90. 130,756 shares of the company's stock traded hands, compared to its average volume of 209,654. The company has a quick ratio of 7.46, a current ratio of 7.88 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $229.62 million, a P/E ratio of -6.36 and a beta of 1.42. AVITA Medical has a 1 year low of $8.01 and a 1 year high of $21.70. The business has a fifty day simple moving average of $13.84 and a two-hundred day simple moving average of $13.57.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on RCEL shares. Piper Sandler reaffirmed an "overweight" rating and issued a $21.00 price target (up previously from $19.00) on shares of AVITA Medical in a report on Friday, February 23rd. Cantor Fitzgerald lifted their target price on shares of AVITA Medical from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, February 23rd. Finally, BTIG Research cut shares of AVITA Medical from a "buy" rating to a "neutral" rating in a research report on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $27.80.
Check Out Our Latest Report on RCEL
About AVITA Medical
(
Get Free Report)
AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.
Further Reading
Before you consider AVITA Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AVITA Medical wasn't on the list.
While AVITA Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
